Daiichi Sankyo Inc. will take the helm on handling U.S. commercialization of the FDA-approved RoxyBond (oxycodone hydrochloride) oral-use medication manufactured by Inspirion Delivery Sciences LLC, the companies announced recently from their respective New Jersey hubs.
Available in three dosage strengths, the product will be marketed as Tablets CII. Inspirion will assist in sales efforts as per a licensing agreement between the two companies. RoxyBond is used to treat severe pain when alternative medications prove insufficient.
“RoxyBond is the first and only FDA-approved immediate-release opioid medication with abuse-deterrent claims in its approved labeling,” spokespersons said.
The partnering firms approach the marketing strategy from an angle of abuse prevention. The medicine is formulated to render injection and/or intranasal ingestion, although technically possible, intentionally problematic to hinder exploitation.
“This combination of abuse-deterrent properties and clinical value for medically appropriate patients makes RoxyBond a good strategic fit for our growing pain franchise,” Daiichi Sankyo’s administrative and commercial president Ken Keller said.
Inspirion’s CEO Dr. Stefan Aigner expressed excitement on behalf of his firm on bringing RoxyBond to the U.S. market, stating that Inspirion looks forward to partnering with Daiichi Sankyo on the venture.
Practitioners are cautioned regarding risks of addiction and misuse with opioids in general.